Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.

[1]  S. Thelin,et al.  Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. , 2008, Artificial organs.

[2]  Dimitrios Morikis,et al.  Solution structure of Compstatin, a potent complement inhibitor , 1998, Protein science : a publication of the Protein Society.

[3]  B. Nilsson,et al.  Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface. , 1997, Immunopharmacology.

[4]  W. Rosse.  Paroxysmal Nocturnal Hemoglobinuria as a Molecular Disease , 1997, Medicine.

[5]  John D Lambris,et al.  Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. , 1996, Journal of immunology.

[6]  L. Matis,et al.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.

[7]  B. Morgan.  Complement regulatory molecules: application to therapy and transplantation. , 1995, Immunology today.

[8]  M. Kirschfink,et al.  Activation of complement by cold agglutinins. , 1994, Infusionstherapie und Transfusionsmedizin.

[9]  B. Nilsson,et al.  Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome associated with a hereditary C3 dysfunction. , 1994, Annals of the rheumatic diseases.

[10]  W. T. Moore.  Integration of Mass Spectrometry into Strategies for Peptide Synthesis , 1993 .

[11]  B. Nilsson,et al.  Evidence for iC3 generation during cardiopulmonary bypass as the result of blood‐gas interaction , 1993, Clinical and experimental immunology.

[12]  W. Baumgartner,et al.  Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[13]  P. Ward,et al.  Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. , 1992, Journal of immunology.

[14]  D. Fearon.  ANTI‐INFLAMMATORY AND IMMUNOSUPPRESSIVE EFFECTS OF RECOMBINANT SOLUBLE COMPLEMENT RECEPTORS , 1991, Clinical and experimental immunology.

[15]  P. Sims,et al.  The response of human platelets to activated components of the complement system. , 1991, Immunology today.

[16]  W. Greeley,et al.  Assessing the effect of cardiopulmonary bypass on the brain. , 1991, The Annals of thoracic surgery.

[17]  M. Oppermann,et al.  Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. , 1991, The Annals of thoracic surgery.

[18]  J. Schifferli,et al.  Purification of human complement factor D from the peritoneal fluid of patients on chronic ambulatory peritoneal dialysis. , 1991, Journal of immunological methods.

[19]  R. Colman,et al.  Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. , 1989, Blood.

[20]  D. Chenoweth,et al.  Complement activation produced by biomaterials. , 1986, Artificial organs.

[21]  S. Frøland,et al.  Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.

[22]  A. Carpentier,et al.  Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. , 1985, The Journal of thoracic and cardiovascular surgery.

[23]  Z. Fishelson,et al.  C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex. , 1983, The Journal of biological chemistry.

[24]  H. Gresham,et al.  Large scale isolation of functionally active components of the human complement system. , 1981, The Journal of biological chemistry.

[25]  H. Müller-Eberhard,et al.  ISOLATION OF A FRAGMENT (C3a) OF THE THIRD COMPONENT OF HUMAN COMPLEMENT CONTAINING ANAPHYLATOXIN AND CHEMOTACTIC ACTIVITY AND DESCRIPTION OF AN ANAPHYLATOXIN INACTIVATOR OF HUMAN SERUM , 1969, The Journal of experimental medicine.

[26]  R. Colman,et al.  Nafamostat Mesilate, a Broad Spectrum Protease Inhibitor, Modulates Platelet, Neutrophil and Contact Activation in Simulated Extracorporeal Circulation , 1996, Thrombosis and Haemostasis.

[27]  R. Johnson,et al.  Complement activation by biomaterials. , 1990, Progress in clinical and biological research.

[28]  M. Kazatchkine,et al.  Activation of the complement system at the interface between blood and artificial surfaces. , 1988, Biomaterials.

[29]  T. Yoshikawa,et al.  Inhibitory effects of FUT-175, a new synthetic protease inhibitor, on intravascular hemolysis by human serum in mice. , 1987, International journal of immunopharmacology.